Suppr超能文献

新型口服前列腺素E1类似物的免疫抑制特性。

The immunosuppressive properties of new oral prostaglandin E1 analogs.

作者信息

Pollak R, Dumble L J, Wiederkehr J C, Maddux M S, Moran M

机构信息

Department of Surgery, University of Illinois, Chicago 60680.

出版信息

Transplantation. 1990 Nov;50(5):834-8. doi: 10.1097/00007890-199011000-00018.

Abstract

Prostaglandins play an important role in cell-mediated immune responses. Their clinical use has been limited by poor oral bioavailability, short half-lives, and significant toxicity profiles. We studied the immunosuppressive properties of new, synthetic, prostaglandin E1 (PGE1) methyl ester analogs (misoprostol, enisoprost) with oral bioavailability using an allogeneic in vitro immunoassay. Our results show that the PGE1 analogs suppress alloproliferative responses and supplement the immunosuppressive activity of cyclosporine and methylprednisolone. Moreover, we demonstrate that addition of recombinant interleukin-2 to the PGE1 analogs restores alloimmune responsiveness and the expression of surface class II antigen and IL-2 receptors on responder lymphocytes. These studies, together with preliminary in vivo data in rodents and man, suggest that the new synthetic oral PGE1 analogs may provide therapeutic efficacy in clinical transplantation and a variety of immunologically mediated diseases.

摘要

前列腺素在细胞介导的免疫反应中发挥重要作用。其临床应用因口服生物利用度差、半衰期短和显著的毒性特征而受到限制。我们使用同种异体体外免疫测定法研究了具有口服生物利用度的新型合成前列腺素E1(PGE1)甲酯类似物(米索前列醇、依索前列醇)的免疫抑制特性。我们的结果表明,PGE1类似物可抑制同种异体增殖反应,并补充环孢素和甲基强的松龙的免疫抑制活性。此外,我们证明,向PGE1类似物中添加重组白细胞介素-2可恢复同种异体免疫反应性以及反应淋巴细胞表面II类抗原和IL-2受体的表达。这些研究,连同在啮齿动物和人类中的初步体内数据,表明新型合成口服PGE1类似物可能在临床移植和多种免疫介导疾病中提供治疗效果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验